Codiak Biosciences Reports Net Loss of $19.3 Million in Q3 2022

Codiak Biosciences,Inc(CDAKQ). has released its financial st atements for the third quarter of 2022, reporting a net loss of $19.3 million. Despite the loss, the company generated $522,000 in revenue during the same period. These figures reflect the company's ongoing efforts in the biotechnology sector as it strives to advance its innovative therapies.**

Net Loss of $19.3 Million in Q3 2022

Codiak Biosciences, Inc., a leading biotechnology company focused on developing exosome-based therapeutics, announced a net loss of $19.3 million for the third quarter of 2022. The loss is attributed to continued investments in research and development activities and general administrative expenses.

The company's net loss per share attributable to common stockholders, both basic and diluted, was reported at $0.77 for the quarter. Codiak Biosciences has been dedicated to advancing its pipeline of therapies and exploring the potential of exosomes as a novel therapeutic modality.